Tetra Bio-Pharma Secures CBD Supply Agreement for Genacol Partnership
Momentum Public Relations
Press Release: September 5, 2018
Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that it has secured a CBD supply agreement with True North Cannabis in Alberta, Canada. Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation which will be commercialized under the previously announced partnership with Genacol.
Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create these innovative products for Genacol. Tetra Bio-Pharma will work with the appropriate regulatory agencies to gain marketing authority within Genacol’s international sales network where their brand products are available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. According to industry statistics the market for topical pain relief products exceeds $2.5 billion. The products are expected to be launched in 2019.
“We are very pleased to secure a competitive supply agreement with True North Cannabis as Tetra is committed on bringing innovative cannabinoid products to market,” says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. “True North Cannabis has built a state-of-the-art facility in Alberta which will provide the highest quality CBD for Tetra, at a competitive price, to develop innovative products in partnership with Genacol. Price to consumers is a critical aspect for the viability of a commercial product in the self-care health market. At Tetra Bio-Pharma we are focused on becoming a global leader in the development of cannabinoid derived prescription and natural health products.”
“True North Cannabis is pleased to enter into a commercial relationship to supply hemp-based CBD to Tetra Bio-Pharma,” Shayne Hamilton, Chief Executive Officer of True North Cannabis commented. “Our business leverages the size and scale of the industrial hemp crop in Canada to provide a competitively priced, reliable source of CBD. Tetra Bio-Pharma’s vast experience in pharmaceutical product development, along with Genacol’s robust distribution footprint, presents True North Cannabis a unique opportunity to market our product.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About True North Cannabis
True North Cannabis (TNC) is a Canadian hemp harvest service provider with a core focus on facilitating the supply of bulk, extract-ready, hemp-based CBD.
With a grower-focused service model, TNC supports industrial hemp growers across Canada to effectively commercialize the cannabinoid content from their harvest. By providing access to state of the art infrastructure and hemp chaff expertise, TNC manages the unique challenges in bridging broad acre agriculture and the Cannabis industry.
For more information visit: www.truenorthcannabis.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
DIAGNOS Partners with Optina Diagnostics, a Montreal Based Company, to Provide a Web Platform for the Early Detection of Alzheimer Disease
Momentum Public Relations
Press Release: September 5, 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an agreement to provide a telemedicine platform based on CARA (Computer Assisted Retina Analysis) to Optina Diagnostics (“Optina”) for a period of 3 years. Optina will use DIAGNOS Cloud services to upload images generated by Optina’s hyperspectral camera for early detection of Alzheimer via key biomarkers in the retina of the eye.
The processed images will be available to be shared and further analysed by healthcare professionals and clinics in various locations. Optina will benefit from the high throughput of DIAGNOS CARA Cloud service as well as the ease of use of the teleophthalmology platform currently used by doctors and other medical professionals.
“At DIAGNOS, we are extremely happy to contribute to the success of innovative Quebec companies like Optina. Optina will leverage our experience and the high quality standard of CARA, a field proven platform approved for sale by the Food and Drug Administration in the United States, Health Canada and other countries’ homologation bodies. This partnership will foster more collaboration with other biotech firms and attract new clients in need of a telemedicine platform.” said Yves-Stephane Couture, Vice-President of sales at DIAGNOS.
“The partnership will greatly accelerate Optina’s commercialization of its Alzheimer diagnostic test, saving critical time to market while providing effective and efficient user experience.” said David Lapointe, President and CEO of Optina.
About Optina
Optina Diagnostics is a Montreal based company focused on the development of technology for the early detection of disease through hyperspectral imaging of the eye. With a first application in the early diagnosis of Alzheimer’s, Optina brings a radiomics approach to biomarker detection.
Additional information about Optina is available at www.optinadx.com.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele- ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
- Published in Business, Diagnos, Life Sciences, News Home, Technology